Literature DB >> 22583437

Optical coherence tomography detection of neurodegeneration in multiple sclerosis.

Katie Lidster1, David Baker.   

Abstract

The pathophysiology of multiple sclerosis (MS) is typically characterised by inflammation and demyelination leading to neurodegeneration, which is associated with disability and the progressive stages of MS. The visual system is a valuable tool for studying neurodegeneration and potential neuroprotection in the central nervous system due to its ease of accessibility. Optical coherence tomography (OCT) is a non-invasive tool, which can be used to measure the thickness of the retinal nerve fibre layer (RNFL). The thickness of RNFL is reduced following the development of MS and optic neuritis and can therefore be used as a correlate of global axonal loss. OCT is currently being investigated as a structural outcome measure for neuroprotective clinical trials of MS. This review describes the relationship between MS and optic neuritis and the associated RNFL thinning, the technology and advancements of OCT, the role of OCT in clinical trials for new neuroprotective therapies in MS and the future role of OCT in MS research.

Entities:  

Mesh:

Year:  2012        PMID: 22583437     DOI: 10.2174/187152712801661185

Source DB:  PubMed          Journal:  CNS Neurol Disord Drug Targets        ISSN: 1871-5273            Impact factor:   4.388


  9 in total

1.  [Optic neuropathy after retrobulbar neuritis in multiple sclerosis: are optical coherence tomography and magnetic resonance imaging useful and necessary follow-up parameters?].

Authors:  R M Dachsel; R Dachsel; S Domke; T Groß; O Schubert; L Kotrini; K Ladegast; J Vogel; T Jordan; S Zawade
Journal:  Nervenarzt       Date:  2015-02       Impact factor: 1.214

2.  Optic Atrophy in End-Stage Giant Axonal Neuropathy: A Case Report.

Authors:  T J Wubben; A O Eghrari; A N McCoy; D J Ramsey
Journal:  Neuroophthalmology       Date:  2013-09-24

3.  Neurofilament light as an immune target for pathogenic antibodies.

Authors:  Fabiola Puentes; Baukje J van der Star; Stephanie D Boomkamp; Markus Kipp; Louis Boon; Isabel Bosca; Joel Raffel; Sharmilee Gnanapavan; Paul van der Valk; Jodie Stephenson; Susan C Barnett; David Baker; Sandra Amor
Journal:  Immunology       Date:  2017-08-11       Impact factor: 7.397

4.  Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis.

Authors:  Silvia Rossi; Marco Bozzali; Monica Bari; Francesco Mori; Valeria Studer; Caterina Motta; Fabio Buttari; Mara Cercignani; Paolo Gravina; Nicolina Mastrangelo; Maura Castelli; Raffaele Mancino; Carlo Nucci; Fabrizio Sottile; Sergio Bernardini; Mauro Maccarrone; Diego Centonze
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

5.  Optical coherence tomography versus visual evoked potential in multiple sclerosis patients.

Authors:  Farzad Fatehi; Vahid Shaygannejad; Lida Kiani Mehr; Alireza Dehghani
Journal:  Iran J Neurol       Date:  2012

6.  Imidazol-1-ylethylindazole voltage-gated sodium channel ligands are neuroprotective during optic neuritis in a mouse model of multiple sclerosis.

Authors:  Lorcan Browne; Katie Lidster; Sarah Al-Izki; Lisa Clutterbuck; Cristina Posada; A W Edith Chan; Dieter Riddall; John Garthwaite; David Baker; David L Selwood
Journal:  J Med Chem       Date:  2014-03-21       Impact factor: 7.446

Review 7.  The retinoprotective role of phenytoin.

Authors:  Silvia Bartollino; Flavia Chiosi; Silvio di Staso; Maurizio Uva; Arduino Pascotto; Michele Rinaldi; Jan M Keppel Hesselink; Ciro Costagliola
Journal:  Drug Des Devel Ther       Date:  2018-10-16       Impact factor: 4.162

8.  Evaluation of the circulating CD34(+), CD309(+), and endothelial progenitor cells in patients with first attack of optic neuritis.

Authors:  Masoud Etemadifar; Leila Dehghani; Hamid Ganji; Reza Soleimani; Maedeh Talebi; Nahid Eskandari; Fazel Sahraneshin Samani; Rokhsareh Meamar
Journal:  Adv Biomed Res       Date:  2015-07-27

9.  Retinal nerve fiber layer sector-specific compromise in relapsing and remitting multiple sclerosis.

Authors:  Anette S Loughran-Fjeldstad; Noel G Carlson; Cassandra D Husebye; Lawrence J Cook; John W Rose
Journal:  eNeurologicalSci       Date:  2015-10-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.